167 related articles for article (PubMed ID: 9222283)
1. Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy.
Wagner SN; Wagner C; Schultewolter T; Goos M
Cancer Immunol Immunother; 1997 Jun; 44(4):239-47. PubMed ID: 9222283
[TBL] [Abstract][Full Text] [Related]
2. pMel17 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and HMB-50 and by anti-melanoma CTL.
Adema GJ; Bakker AB; de Boer AJ; Hohenstein P; Figdor CG
Br J Cancer; 1996 May; 73(9):1044-8. PubMed ID: 8624261
[TBL] [Abstract][Full Text] [Related]
3. Expression cloning of the cDNA encoding a melanoma-associated Ag recognized by mAb HMB-45. Identification as melanocyte-specific Pmel 17 cDNA.
Wagner SN; Wagner C; Höfler H; Atkinson MJ; Goos M
Lab Invest; 1995 Aug; 73(2):229-35. PubMed ID: 7637323
[TBL] [Abstract][Full Text] [Related]
4. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
5. Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo.
Wagner SN; Wagner C; Lührs P; Weimann TK; Kutil R; Goos M; Stingl G; Schneeberger A
J Invest Dermatol; 2000 Dec; 115(6):1082-7. PubMed ID: 11121145
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones.
Sensi M; Pellegatta S; Vegetti C; Nicolini G; Parmiani G; Anichini A
Tissue Antigens; 2002 Apr; 59(4):273-9. PubMed ID: 12135425
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of the melanocyte lineage-specific antigen gp100.
Adema GJ; de Boer AJ; Vogel AM; Loenen WA; Figdor CG
J Biol Chem; 1994 Aug; 269(31):20126-33. PubMed ID: 7519602
[TBL] [Abstract][Full Text] [Related]
8. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.
Marincola FM; Hijazi YM; Fetsch P; Salgaller ML; Rivoltini L; Cormier J; Simonis TB; Duray PH; Herlyn M; Kawakami Y; Rosenberg SA
J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):192-205. PubMed ID: 8811494
[TBL] [Abstract][Full Text] [Related]
9. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.
Seiter S; Monsurro V; Nielsen MB; Wang E; Provenzano M; Wunderlich JR; Rosenberg SA; Marincola FM
J Immunother; 2002; 25(3):252-63. PubMed ID: 12000867
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.
Cormier JN; Hijazi YM; Abati A; Fetsch P; Bettinotti M; Steinberg SM; Rosenberg SA; Marincola FM
Int J Cancer; 1998 Feb; 75(4):517-24. PubMed ID: 9466650
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development.
Chen YT; Stockert E; Tsang S; Coplan KA; Old LJ
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8125-9. PubMed ID: 7667256
[TBL] [Abstract][Full Text] [Related]
12. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.
Rothberg BE; Moeder CB; Kluger H; Halaban R; Elder DE; Murphy GF; Lazar A; Prieto V; Duncan LM; Rimm DL
Mod Pathol; 2008 Sep; 21(9):1121-9. PubMed ID: 18552823
[TBL] [Abstract][Full Text] [Related]
13. Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells.
Klarquist J; Barfuss A; Kandala S; Reust MJ; Braun RK; Hu J; Dilling DF; McKee MD; Boissy RE; Love RB; Nishimura MI; Le Poole IC
Am J Pathol; 2009 Dec; 175(6):2463-72. PubMed ID: 19893037
[TBL] [Abstract][Full Text] [Related]
14. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
Kawakami Y; Eliyahu S; Delgado CH; Robbins PF; Sakaguchi K; Appella E; Yannelli JR; Adema GJ; Miki T; Rosenberg SA
Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6458-62. PubMed ID: 8022805
[TBL] [Abstract][Full Text] [Related]
15. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
16. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
[TBL] [Abstract][Full Text] [Related]
17. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma.
Du J; Miller AJ; Widlund HR; Horstmann MA; Ramaswamy S; Fisher DE
Am J Pathol; 2003 Jul; 163(1):333-43. PubMed ID: 12819038
[TBL] [Abstract][Full Text] [Related]
18. Immune selection after antigen-specific immunotherapy of melanoma.
Riker A; Cormier J; Panelli M; Kammula U; Wang E; Abati A; Fetsch P; Lee KH; Steinberg S; Rosenberg S; Marincola F
Surgery; 1999 Aug; 126(2):112-20. PubMed ID: 10455872
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.
Cormier JN; Abati A; Fetsch P; Hijazi YM; Rosenberg SA; Marincola FM; Topalian SL
J Immunother; 1998 Jan; 21(1):27-31. PubMed ID: 9456433
[TBL] [Abstract][Full Text] [Related]
20. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.
Ramakrishna V; Treml JF; Vitale L; Connolly JE; O'Neill T; Smith PA; Jones CL; He LZ; Goldstein J; Wallace PK; Keler T; Endres MJ
J Immunol; 2004 Mar; 172(5):2845-52. PubMed ID: 14978085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
